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ABSTRACT
Objectives: Several studies suggest that overall and
central-obesity are associated with increased breast
cancer (BC) risk in postmenopausal-women. However,
there are no studies investigating changes of central
obesity and BC. We report on the association of BC
risk with self-reported skirt size (SS; waist-
circumference proxy) changes between 20s and
postmenopausal-age.
Design: Prospective cohort-study.
Setting: UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS) involving the nine trial centres
in England.
Participants: Postmenopausal-women aged >50 with
no known history of BC prior to or on the day of
completion of the study-entry questionnaire.
Interventions: At recruitment and at study entry,
women were asked to complete a questionnaire.
Women were followed-up via ‘flagging’ at the NHS
Information Centre in England and the Hospital
Episode Statistics.
Main outcome-measure: Time to initial BC
diagnosis.
Results: Between 2 January 2005 and 1 July 2010,
92 834 UKCTOCS participants (median age 64.0)
completed the study-entry questionnaire. During
median follow-up of 3.19 years (25th–75th centile:
2.46–3.78), 1090 women developed BC. Model
adjusted analysis for potential confounders showed
body mass index (BMI) at recruitment to UKCTOCS (HR
for a 5 unit change=1.076, 95% CI 1.012 to 1.136),
current SS at study entry (HR=1.051; 95% CI 1.014 to
1.089) and change in SS per 10 years (CSS)
(HR=1.330; 95% CI 1.121 to 1.579) were associated
with increased BC risk but not SS at 25 (HR=1.006;
95% CI 0.958 to 1.056). CSS was the most predictive
singe adiposity measure and further analysis including
both CSS and BMI in the model revealed CSS remained
significant (HR=1.266; 95% CI 1.041 to 1.538) but not
BMI (HR=1.037; 95% CI 0.970 to 1.109).
Conclusions: CSS is associated with BC risk
independent of BMI. A unit increase in UK SS (eg, 12–14)
every 10-years between 25 and postmenopausal-age is
associated with postmenopausal BC risk by 33%.
Validation of these results could provide women with a
simple and easy to understand message.
Trial registration number: ISRCTN22488978.
INTRODUCTION
Breast cancer is a major global health
concern with 1 384 000 women being diag-
nosed every year.1 Signiﬁcant advances in
Strengths and limitations of this study
▪ To the best of our knowledge, this is the first
study investigating the association between
central obesity using skirt size (SS) as a proxy
and breast cancer risk. Between 25 and postme-
nopausal age, an increase in SS by one unit
every decade increased the risk of postmenopau-
sal breast cancer by 33% while decrease in SS
was associated with lowering of risk.
▪ Our prospective cohort-study includes 94 000
women with comprehensive follow-up through
data linkage to multiple national databases.
▪ There is a possibility of underestimation of self-
reported SS. However, if current SS at study
entry is uniformly underestimated then there is
merely rescaling of CSS so that the strength of
the association is unaffected. Furthermore, recall
bias of the SS at 25 maybe a limitation but
unless this inability in reporting is systematically
related to future breast cancer, measurement
error can only result in underestimating the
strength of the true association between CSS
and breast cancer risk.
▪ Given that obesity is now emerging as a global
epidemic, from a public health prospective these
findings are significant as they provide women
with a simple and easy to understand message.
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breast cancer prevention have been accompanied by
growing controversies regarding breast cancer screening.
Both highlight the need for better risk stratiﬁcation.
During the past few years a growing number of studies
have reported on anthropometric factors, particularly on
the relationship between breast cancer risk and overall
and/or central obesity.2–4
A number of adiposity measures exist. The oldest and
most common measure is body mass index (BMI) which
is an empirical proxy for human body fat based on an
individual’s weight and height. Central fat is another
measure of obesity. It is usually estimated by waist cir-
cumference, waist–hip ratio, waist–height ratio or the
conicity index which evaluates waist circumference in
relation to height and weight. An adequate and easy to
use proxy measure for waist circumference is clothing
(trouser/skirt) size, which has been shown to provide a
reliable and feasible estimate of waist circumference at
the population level.5 It has been suggested that waist
circumference independent of BMI, maybe predictive of
increased health risk.6
There is a large body of evidence that high BMI is
associated with increased breast cancer risk in postmeno-
pausal women and reduced risk in premenopausal
women.3 4 7 Another suggested breast cancer risk pre-
dictor is adult weight gain, which typically reﬂects an
increase in body fat.8–10 Results concerning weight loss
are more equivocal; there are studies that show no sig-
niﬁcant effect on risk, while some suggest postmenopau-
sal weight loss may be protective.8 11–14 Furthermore, the
association of central obesity with breast cancer risk is
unclear with studies reporting conﬂicting results.2 15
Among postmenopausal women, several studies16–23 but
not all13 24–28 have shown waist circumference or
waist-to-hip ratio to be positively associated with
increased breast cancer risk.29 There are, however, no
studies examining changes in waist circumference or
waist-to-hip ratio and breast cancer risk.
The UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS),30 with comprehensive follow-up,
provides the opportunity to examine the association of
body size changes with breast cancer risk in a large pro-
spective cohort. Furthermore, the availability of socio-
economic, reproductive, lifestyle and cancer family
history data makes it possible to adjust for many potential
confounders of breast risk.
METHODS
Setting
UKCTOCS is a multicentre randomised controlled trial
of ovarian cancer screening in the general population.
The trial invited 1.2 million women of whom 202 638
were recruited between 17 April 2001 and 27 September
2005 through 13 trial centres in England, Wales and
Northern Ireland. The detailed trial design and eligibil-
ity criteria have been described elsewhere.30 All partici-
pants completed a questionnaire at recruitment and a
further postal follow-up questionnaire 3–4 years post-
recruitment. The latter was the study-entry questionnaire
for the current analysis. Follow-up was through a ‘ﬂag-
ging study’ with the Health and Social Care National
Health Service (NHS) Information Centre who provided
regular notiﬁcations of cancer registrations or deaths in
the cohort. In addition, data linkage to the Hospital
Episode Statistics (HES) an administrative database in
England provided information on all inpatient and out-
patient NHS hospital visits.
Women provided written consent for use of their data
in secondary studies. Ethical approval was obtained from
the Joint University College London (UCL)/UCL
Hospital Committees on the Ethics of Human Research
(REC reference:06/Q0505/102, June 2008).
Subjects
Participants recruited from England who returned the
study-entry questionnaire prior to 2 July 2010 (censor-
ship date—see ‘breast cancer notiﬁcation’). Women
recruited from Northern Ireland and Wales were
excluded as HES was only available for women residing
in England.
Data collection
Questionnaires
Recruitment questionnaire: This was completed at recruit-
ment into UKCTOCS and included information on the
variables listed in tables 1 and 2. This included height
and weight used to calculate BMI, the postcode which
Table 1 Baseline characteristics and HRs for breast cancer for adiposity measures and potential confounders (continuous
variables)
Factor Mean SD
25th
centile
50th
centile
75th
centile HR
Lower
95% CI
Upper
95% CI p Value
Skirt size at age 25 years 12.509 2.533 12 12 14 1.008 0.962 1.056 0.736
Skirt size at study entry 15.133 3.452 12 14 16 1.045 1.011 1.081 0.01
CSS 0.334 0.359 0.191 0.287 0.533 1.283 1.09 1.51 0.003
BMI 26.449 4.783 23.203 25.598 28.821 1.061 1.006 1.119 0.029
IMD 0.011 1.01 −0.685 −0.327 0.458 1.008 0.952 1.068 0.778
Age at last period 48.975 6.009 46.264 49.977 52.703 1.024 1.014 1.035 <0.001
Age at first period 12.959 1.607 12 13 14 1.02 0.983 1.06 0.293
BMI, body mass index at recruitment (5 kg/m2); CSS, change of skirt size per 10 years.
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Table 2 Baseline characteristics and HRs for breast cancer for potential confounders (categorical variables)
Categorical variable
All women
HR
Lower
95% CI
Upper
95% CI p ValueN (%)
Ethnicity
White 90 011 (97.35) ref
Black 832 (0.90) 1.307 0.622 2.75 0.48
Asian 490 (0.53) 0.827 0.443 1.541 0.549
Chinese 166 (0.18) 0.554 0.078 3.936 0.555
Other 669 (0.72) 0.693 0.288 1.668 0.413
No O-level 56 856 (61.24) ref
O-level 35 986 (38.76) 1.208 1.07 1.363 0.002
No A-level 78 436 (84.48) ref
A-level 14 406 (15.52) 1.204 1.03 1.407 0.02
No Clerical or commercial qualification 67 075 (72.25) ref
Clerical or commercial qualification 25 767 (27.75) 1.085 0.953 1.236 0.219
Education
No nursing or teaching 79 668 (85.81) ref
Nursing or teaching 13 174 (14.19) 1.051 0.888 1.243 0.565
No degree college/university 74 640 (80.39) ref
Degree college/university 18 202 (19.61) 1 0.859 1.163 0.996
No other than above qualification 64 090 (69.03) ref
Other than above qualification 28 752 (30.97) 0.828 0.724 0.947 0.006
Hysterectomy with ovarian conservation at recruitment
No 76 318 (82.20) ref
Yes 16 524 (17.80) 0.961 0.821 1.125 0.621
Oral contraceptive pill use
No 37 083 (39.94) ref
Yes 55 759 (60.06) 0.97 0.852 1.106 0.654
Hormone replacement therapy use at recruitment
No 73 544 (79.21) ref
Yes 19 298 (20.79) 1.12 0.971 1.289 0.118
Hormone replacement therapy use at study entry
No 85 866 (92.50) ref
Yes 6963 (7.50) 1.232 1 1.517 0.049
Sterilisation
No 74 550 (80.30) ref
Yes 18 292 (19.70) 0.951 0.817 1.108 0.523
Infertility treatment
No 72 731 (78.34) ref
Yes 20 111 (21.66) 1.459 1.103 1.93 0.008
Pregnancies less than 6 months
0 64 126 (69,90) ref
1 18 896 (20.60) 1.124 0.971 1.302 0.116
2 5596 (6.10) 0.966 0.742 1.256 0.795
3 1790 (1.95) 1.521 1.055 2.192 0.024
4 649 (0.71) 1.690 0.955 2.990 0.071
5 678 (0.74) 0.957 0.454 2.014 0.907
Pregnancies more than 6 months
0 10 986 (11.87) ref
1 11 297 (12.18) 1.023 0.821 1.276 0.837
2 40 890 (44.17) 0.768 0.640 0.923 0.005
3 20 007 (21.61) 0.767 0.624 0.944 0.012
4 6612 (7.14) 0.824 0.626 1.084 0.625
5 2804 (3.03) 0.594 0.386 0.915 0.385
Alcohol (units per week) at study entry
None 21 086 (22.97)
Less than 1 16 084 (17.52) 1.011 0.835 1.226 0.905
1–3 18 717 (20.39) 1.062 0.886 1.275 0.511
4–6 13 813 (15.05) 1.039 0.851 1.267 0.71
7–10 11 056 (12.04) 0.949 0.762 1.181 0.64
Continued
Fourkala E-O, et al. BMJ Open 2014;4:e005400. doi:10.1136/bmjopen-2014-005400 3
Open Access
group.bmj.com on August 10, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
was used to derive the Index of Multiple Deprivation
(IMD; with lower scores indicating less deprived areas),
age at ﬁrst and last period, number of pregnancies, hys-
terectomy, sterilisation, infertility and breast and ovarian
cancer family history, past oral contraceptive pill use,
current hormone replacement therapy (HRT) use.
Study-entry questionnaire : This was completed at
follow-up (3–4 years after recruitment) and provided
information on education, skirt size, continuing use of
HRT, smoking, alcohol use, health status and cancer diag-
nosis postrecruitment (tables 1 and 2). The date of com-
pletion of this questionnaire was the entry date for the
current study. This was available in 89.8% of the women.
Where this date was missing, the date of questionnaire
data entry into the trial management system was used.
Breast cancer notification
The ICD-9 and ICD-10 codes used to identify women
with breast cancer were 174* and C50*, respectively.
Up-to-date data records from the NHS Information
Centre and HES were searched to identify women with a
breast cancer diagnosis. Women also self-reported breast
cancer. Both at recruitment and at current study entry,
women were asked speciﬁcally whether they had ever
been diagnosed with breast cancer and if so, details of
diagnosis date and details of treating physician.31 Overall
there was a good concordance between the different
sources used to identify the breast cancer cases.31 32
As there can be delays in cancer notiﬁcation by the
National Health and Social Care NHS Information
Centre,31 the censorship date was set as 1 July 2010,
2 years prior to the date (10 July 2012) when data was
provided by the NHS Information Centre agencies for
this analysis. This ensured that as far as possible, all
breast cancers in the stated period of observation were
registered and therefore included. HES data was avail-
able for all the participants for the period between
6 August 1998 when HES started and 31 March 2010.
Exposure variables
Self-reported height and weight were taken from the
recruitment questionnaire and used to calculate BMI
(with one unit equal here to 5 kg/m2). In the study-
entry questionnaire two speciﬁc questions related to
skirt size (SS) were asked: (1) ‘What was your SS when
you were in your twenties?’ (2) ‘What is your SS now?’
Women could choose from 13 SS categories ranging
from 6 to 30. The two SS questions were used to create a
variable reﬂecting change in SS over time. The change
in SS variable (CSS) was calculated as an increase in SS
per 10 years. Note that a ‘one unit’ increase in SS means
an increase by two nominal values, for example from
size 10 to size 12 as odd sizes do not exist in the UK.
Statistical analysis
Standard survival analysis methods were used to analyse
the data. Cox models were preferred so that speciﬁca-
tion of an underlying hazard was not required. Women
with breast cancer previous to questionnaire completion
date were excluded from the analysis. The date of study-
entry questionnaire was the time point used for entry
into study. However, there was delayed entry (left trunca-
tion) in that they were only able to participate in the
current study because they ‘survived’ (had not died,
withdrawn from trial or got breast cancer) the period
from their mid-20s (the ﬁrst skirt size question) to study-
entry questionnaire completion date (the second
current skirt size question). To account for a woman’s
contribution to the analysis being conditional on having
‘survived’ during the unobserved period, the length of
which depends on the age at study entry, the timescale
used was age rather than date. Therefore, the time
origin was ﬁxed at age=25 for all participants and study
entry was age at completion of study-entry questionnaire.
Women were censored either at age at ﬁrst breast
cancer, death from any cause or 1 July 2010 whichever
occurred ﬁrst.
Table 2 Continued
Categorical variable
All women
HR
Lower
95% CI
Upper
95% CI p ValueN (%)
11–15 6549 (7.13) 0.985 0.758 1.279 0.91
16–30 2990 (3.26) 1.271 0.92 1.745 0.146
21+ 1501 (1.64) 1.331 0.866 2.044 0.192
Smoking
0 51 470 (56.27) ref
250 21 661 (23.68) 0.958 0.825 1.113 0.574
500 9632 (10.53) 1.032 0.847 1.259 0.752
750 8706 (9.52) 1.153 0.947 1.403 0.156
Relatives breast cancer history
No 72, 731 (78.34) ref
Yes 20 111 (21.66) 1.48 1.298 1.687 <0.0005
Relatives ovarian cancer history
No 88 878 (95.73) ref
Yes 3964 (4.27) 0.946 0.699 1.279 0.718
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Summaries of all identiﬁed potential confounding risk
factors were performed. These variables were also
included individually in a Cox regression model to
obtain univariable estimates of their HR relating to
breast cancer risk. In addition kernel density plots of all
four adiposity measures were created and Pearson cor-
relation coefﬁcients were calculated for all adiposity
measure-pairings. To obtain an appropriate confounder-
adjusted estimate of the relative hazard of breast cancer
of increasing SS, a Cox regression model including CSS
in continuous form with all potential risk factors, regard-
less of statistical signiﬁcance, was ﬁtted (the ‘full
model’). The functional form for CSS was determined
using fractional polynomials, by considering powers
from the standard predeﬁned set {−2, −1, −0.5, 0, 0.5, 1,
2, 3} and modelling the most appropriate relationship
between CSS and the (log) relative hazard. The full
model was reﬁtted with each of the adiposity measures
forming the exposure variable, in turn. In addition, a
variant formulation of the full model included both CSS
and BMI and both SS at current study entry and BMI.
Cox-Snell residuals were used to test the model ﬁt and
the proportional hazards assumption used in Cox regres-
sion was tested using the scaled Schoenfeld residuals for
each variable in the ﬁnal model. The (undue) inﬂuence of
any outliers was assessed by calculating the change in the
parameter estimate when an observation is deleted. To visu-
alise the ‘dose-response’ relationship model, predicted rela-
tive hazards with 95% conﬁdence bands for a range of CSS
values were plotted. To obtain estimates of absolute risk for
certain scenarios (when CSS=0, CSS=1, CSS=median
value), the event density function was assumed to be expo-
nentially distributed and the full model with CSS was ﬁtted
again using exponential regression. Survival curves with
the same covariate pattern following both the Cox and
exponential model ﬁtting were plotted to ensure that the
constant hazard was a reasonable assumption when aver-
aged over the timeframe. An estimate of absolute risk was
calculated by using the covariate-speciﬁc hazard from the
exponential model for 1 and 5 years.
Sensitivity analyses
To guard against the possibility of reverse causality whereby
preclinical breast cancer may result in weight gain, the full
model with CSS was reﬁtted but with a time-lag of 1 year so
that the start of the study period occurs 1 year after comple-
tion of the study-entry questionnaire.
In the primary analysis, missing data in CSS or any
other confounder was handled by case-wise deletion. To
assess the robustness of estimation with such an
approach to potential biases, multiple imputation (MI)
was used to calculate the corresponding model estimates
with missing data imputed appropriately. Speciﬁcally, a
multivariate normal distribution formed by all potential
predictors and the outcome variables (event and time)
was used for the imputed random draws, and 20 fully
imputed data sets were created with which to obtain
valid estimates and SEs.
RESULTS
A total of 157 997 women residing in England were
recruited to the trial between 17 April 2001 and 29
September 2005. Of 11 659 (9440 withdrew, 533 moved
away, 1686 died) women were not sent the study-entry
questionnaire. The remaining 146 338 women were sent
the study-entry questionnaire between 28 June 2005 and
17 March 2009 and 112 945 (77.2%) responded by 31
December 2010. A total of 10 689 of these women com-
pleted the current study-entry questionnaire after the cen-
sorship date of 1 July 2010 and were therefore excluded.
Eight women did not give consent for ﬂagging. The
remaining 102 249 were successfully ﬂagged with the
NHS Information Centre. Of these, 62 were lost to
follow-up by the NHS Information Centre prior to ques-
tionnaire completion, 9342 were diagnosed with breast
cancer before or on the day of completion of the study-
entry questionnaire and in 10, study-entry questionnaire
completion date could not be calculated. The remaining
92 834 women were included in the study and were
followed-up for a median of 3.19 years (25th–75th
centile: 2.46–3.78 years). During the study period, 1090
women developed breast cancer, resulting in an absolute
risk of breast cancer of 1.2% (1090/92 834) in this
cohort of postmenopausal women, 75% of whom were
aged over 60 years with no prior history of breast cancer.
More information regarding the age distribution of the
cohort is provided in online supplementary ﬁgure S1.
The reproductive and lifestyle characteristics of the
92 834 women included in the analysis are summarised
in tables 1 and 2. Brieﬂy, the women were mainly White,
with a median year of birth at 1943 (IQR: 1937–1947),
19.6% had a University degree and their median stan-
dardised—IMD (using 2008 data) was −0.327 (IQR:
−0.685–0.458) indicating that most women are from less
deprived areas. Most women were overweight (median
BMI 25.598, (IQR: 23.203–28.821) at trial recruitment
(median recruitment age 60.2; IQR: 55.8–65.8), had a
median SS at 25 of 12 (IQR: 12–14) and at study entry
of 14 (IQR: 12–16) (median age 64.0; IQR: 59.7–69.7).
The median CSS was 0.287 (IQR: 0.191–0.533) per
10 years, which is equivalent to an increase of 1 unit in
SS (eg, 10–12) in almost 35 years. Figure 1 shows the dis-
tribution for the four adiposity measures where CSS is
largely symmetrical while the other three measures
display some positive skewness.
The Pearson’s correlation coefﬁcients for the different
adiposity measures are presented in table 3. All of them
were relatively high correlated apart from SS at 25 with
CSS. Among the univariable Cox regressions, all mea-
sures of adiposity had signiﬁcant HRs at the 5% level,
except for SS at 25 (tables 1 and 2). Other signiﬁcant
predictors of breast cancer risk were age at last period,
number pregnancies greater than 6 months, infertility
treatment, family history of breast cancer and HRT use
at current study entry (tables 1 and 2).
A total of 5500 women were not included in the
model due to missing values for either CSS or a
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confounder. The remaining 87 334 women, 1013 of
whom developed breast cancer during follow-up were
included in the full Cox model with CSS. Use of frac-
tional polynomials of the CSS variable showed the most
appropriate functional form was linear, with tests of
better ﬁt for other powers of degrees 1 (p=0.719) and 2
(p=0.981) showing no improvement. Confounder-
adjustment revealed a stronger positive association
between CSS and breast cancer risk (HR=1.330 per
10 years; 95% CI 1.121 to 1.579; p=0.001) than without
adjustment (table 4). For each unit increase in SS per
10 years the hazard rate of breast cancer increased by
33%. Replacement of CSS with the other adiposity mea-
sures in a full model, again showed a signiﬁcant but lesser
association between BMI (HR=1.076 per 5 units; 95% CI
1.018 to 1.136; p=0.009) and SS at study entry (HR=1.051;
95% CI 1.014 to 1.089; p=0.006) with breast cancer risk,
but not for SS at 25 (HR=1.006; 95% CI 0.958 to 1.056;
p=0.809). Including recruitment BMI into the full model
with CSS showed some sharing of predictive power but
CSS had an association with breast cancer risk independ-
ent of BMI (HR=1.27; 95% CI 1.041 to 1.538; p=0.018 for
CSS; HR=1.04; 95% CI 0.970 to 1.109; p=0.287 for recruit-
ment BMI; table 4). A full model with SS at study entry
(HR=1.037; 95% CI 0.992 to 1.085; p=0.109) and BMI
(HR=1.037; 95% CI 0.964 to 1.116; p=0.329) suggested less
independence between the two measures than between
CSS and BMI and neither variable was statistically signiﬁ-
cant at α=0.05 (table 4).
Tests and plots based on the Schoenfeld residuals
showed no evidence of any violation of the proportional
hazards assumption. Online supplementary ﬁgure S2
plots these residuals for CSS with a superimposed
smoother and shows that the effect of CSS on breast
cancer risk is essentially stable over the entire age range
considered in this study. The Cox-Snell residuals plotted
against their cumulative hazard showed a virtual line of
unity indicating good model ﬁt (ﬁgure not shown).
Similar diagnostic results were found using the other
adiposity measures.
Figure 1 Relative hazards for a range of skirt size (SS) changes per 10 years (CSS) with 95% confidence bands.
Table 3 Pearson correlation coefficients between skirt size at 25, and at study entry (follow-up questionnaire completion),
change in skirt size (CSS) per 10 years and body mass index (BMI) at recruitment
Skirt size at 25 Skirt size at study entry BMI at recruitment CSS
Skirt size at 25 1.000
Skirt size at study entry 0.606 (p<0.0005) 1.000
BMI 0.330 (p<0.0005) 0.643 (p<0.0005) 1.000
CSS −0.153 (p<0.0005) 0.693 (p<0.0005) 0.497 (p<0.0005) 1.000
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Figure 2 shows how the model relates breast cancer
risk to varying changes in SS. For example, for those
with an increase of 2 SS every 10 years, the estimated
relative hazard increases by 77% (HR=1.769; 95% CI
1.164 to 2.375). Online supplementary ﬁgure S3 shows
the estimated survival functions when CSS=0, CSS=1 and
CSS=0.287 (the median CSS value), with other continu-
ous covariates set to their mean value and categorical
variables set to their base value and starting at the earli-
est observed age entering the study. These functions are
plotted for both the Cox and exponential model and
show that the exponential model is a reasonable
approximation over the timeframe considered here. The
derived estimates of absolute risk for 1 year were 0.33%
(95% CI 0.30% to 0.36%) when CSS=0 and 0.43% (95%
CI 0.37% to 0.48%) when CSS=1 (exponential model
HR=1.31). These estimates compare with 0.35% (95%
CI 0.33% to 0.38%) when CSS=0.287 (median CSS) and
the raw incidence rate of 0.38% (1090 cancers in 3.07
mean study years). The 5 year absolute risks are 1.63%
(95% CI 1.48% to 1.77%) when CSS=0 and 2.14% (95%
CI 1.87% to 2.40%) when CSS=1 and a raw incidence
rate (number of cancers per 5 years of study time across
sample) of 1.91%.
A sensitivity analysis added a time-lag of 1 year to the
primary analysis that used the full model with CSS. For
this regression model only 86 284 women were included
as 1 121 women were left-censored before 1 year, includ-
ing 71 who had missing covariate data. The HR of 1.422
(95% CI 1.149 to 1.758; p=0.001) is slightly larger com-
pared to the primary analysis but not substantively differ-
ent (table 4).
A multiple imputation analysis was carried out to inves-
tigate the effect of missing data on the model estimation.
Data were missing for one or more variables in 5.9% and
for CSS in 1.2% of the sample. Twenty completed data
sets were created using multiple imputation and the sub-
sequent HR=1.300 (95% CI 1.102 to 1.534; p=0.002)
(table 4) and SE estimate for CSS was essentially
unchanged compared to the case-wise model result.
DISCUSSION
This is to date the only study that we are aware of investi-
gating the association of change in SS and breast cancer
risk. Our data suggests that a unit increase in UK SS (eg,
12–14) every 10 years between the 20s and postmeno-
pausal age increases the risk of postmenopausal breast
cancer by 33%. We estimated an increase in 5-year abso-
lute risk of postmenopausal breast cancer from 1 in 61
to 1 in 51 with each unit increase in SS per 10 years.
Table 4 Confounder-adjusted Cox model estimates for various adiposity measures and their association with breast cancer
risk
Measures of adiposity Effective sample size Number of events HR Lower 95% CI Upper 95% CI p Value
Full model with individual adiposity measure
CSS 87 334 1013 1.33 1.121 1.579 0.001
Skirt size at 25 87 783 1017 1.006 0.958 1.056 0.829
Skirt size at study entry 87 661 1018 1.051 1.014 1.089 0.006
BMI at recruitment 87 615 1021 1.076 1.012 1.136 0.009
Full model with specific adiposity measure combinations
CSS 86 678 1008 1.266 1.041 1.538 0.018
BMI 1.037 0.97 1.109 0.287
Skirt size at study entry 87 003 1013 1.037 0.992 1.085 0.109
BMI 1.037 0.964 1.116 0.329
Full model with one year time lag
CSS 86 284 650 1.422 1.149 1.758 0.001
Full model with multiple imputation model
CSS 92 834 1090 1.3 1.102 1.534 0.002
Full model means adjusted for all potential confounders: Index of Multiple Deprivation (IMD), age at first and last period, number of
pregnancies, hysterectomy, sterilisation, infertility, breast and ovarian cancer family history, oral contraceptive use (pill) use, hormone
replacement therapy (HRT) use (from recruitment questionnaire); education, skirt size, continuing use of HRT, smoking, alcohol use, health
status and cancer diagnosis (from study-entry questionnaire).
BMI, body mass index at recruitment per 5 kg/m2; CSS, change of skirt size per 10 years.
Figure 2 Distribution for skirt size (SS) at 20 s, skirt size at
current entry-study, BMI at recruitment and change of skirt
size (CSS) every 10 years.
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Reductions in SS decreased the risk of breast cancer
(ﬁgure 2) though it should be noted that for 76% of
the women in this study, SS increased over their adult
lifetime. These ﬁndings may provide women with a
simple and easy to understand message given that SS has
been found to be a reliable measure for changes in waist
circumference and one that women may relate and
understand better in comparison to other adiposity mea-
sures such as BMI.5
The major strengths of this study are its prospective
cohort design, sample size, comprehensive follow-up
through national registries and administrative databases
and self-reporting resulting in high-quality data.
Evaluation of numerous possible confounders including
life style choices and socioeconomic status minimised
bias. Owing to missing data in the covariates, case-wise
deletion meant 5508 women were dropped from the
Cox regression model. However, a sensitivity analysis
using 20 completed sets of multiply imputed data
showed that the missing data had little effect on the
overall outcome of the study. Furthermore, the study
conclusions were maintained after introducing a
time-lag of 1 year to the study entry to rule out reverse
causality. The absolute risk of breast cancer in this
cohort over a median follow-up of 3.2 years was 1.2% as
only postmenopausal women with no prior history of
breast cancer, 75% of whom were aged over 60 years,
were included in this analysis. In keeping with other
studies, family history of breast cancer, infertility, age at
last period, HRT use were associated with increased
breast cancer risk while pregnancies lasting over
6 months were protective.33 Limitations of the study are
the relatively short follow-up period, the possibility of
underestimation of self-reported SS and recall bias of SS
at 25. However, if current SS is uniformly underestimated
across the sample then there is merely a rescaling of the
CSS variable so that the strength of the relationship is
unaffected, although the HR relating to a unit increase
would be smaller. The same scenario applies to possible
modern downsizing in SS to reﬂect increasing BMI (eg, a
SS of 12 in their mid-20s is now equivalent to, say, a SS of
10) assuming that this downsizing trend does not notice-
ably occur over the period of ‘current study-entry SS’. All
dates of FU questionnaire were between 2005 and 2010
with 97% between 2006 and 2009. The true relationship
would only be weaker than reported if underestimation
was not random but more prevalent among those who
got breast cancer compared to those that did.
Furthermore, unless the inability to accurately recall SS
in the 20 s is systematically related to future breast cancer
or a confounder, measurement error can only result in
underestimating the strength of the true relationship
between CSS and risk of breast cancer.
The ﬁndings that CSS is associated with breast cancer
risk (CSS per 10 years HR=1.33, 95% CI 1.12 to 1.58;
p=0.0010) and that addition of BMI to the model does
not signiﬁcantly improve risk prediction, are consistent
with previous studies addressing the relationship
between body weight and breast cancer risk showing
that adult weight gain is a better predictor of breast
cancer risk than absolute weight or BMI.8–10 29 Increases
in waist circumference have also been reported to
increase risk of other cancers such as pancreatic,34 endo-
metrial35 and ovarian36 cancer. A more equivocal issue
in the literature is whether weight loss has a protective
effect. Our ﬁndings that a decrease in SS is associated
with decreased risk are in line with the studies showing
reduction of weight can reduce risk of postmenopausal
breast cancer.8 11
Current SS (at postmenopausal age; HR=1.05, 95% CI
1.01 to 1.09), but not SS in the 20 s, was associated with
a statistically signiﬁcant increase in breast cancer risk
and appears to be a better predictor compared to BMI.
Our ﬁndings come in agreement with other studies29
and in keeping with the ﬁndings of a comparison of adi-
posity measures in postmenopausal women where waist
circumference was found to be a stronger risk factor
than BMI for a variety of conditions.37 Absolute waist cir-
cumference has also been associated with increased risk
of other cancers such as lung38 and colon.39
In our study changes in SS was a better predictor of
breast cancer risk compared to absolute SS in terms of
strength of association. Although the exact mechanism of
these relationships need to be better understood, there is
a suggestion that body fat around the waist is more meta-
bolically active than adipose tissue elsewhere.40 Obesity is
known to increase oestrogen levels as a result of aromatisa-
tion of androstenedione in adipose tissue as well as affect
insulin resistance and chronic inﬂammation, well known
factors shown to increase breast cancer risk.41
CONCLUSION
Convincing evidence is available that high-body weight,
BMI and adult weight gain, which typically reﬂect an
increase in body fat, are associated with increased breast
cancer risk. To the best of our knowledge, this is the ﬁrst
study investigating the association of waist changes using
SS as a proxy and breast cancer risk. Between 20s and
postmenopausal age, an increase in skirt size by one unit
every decade increases the risk of postmenopausal breast
cancer by 33%. Validation of these results could provide
women with a simple and easy to understand message.
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